| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/30/2003 | WO2003008384A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 01/30/2003 | WO2003008373A1 Tyrosine hydrazides |
| 01/30/2003 | WO2003008371A1 Substituted 4-aminocyclohexanol derivatives |
| 01/30/2003 | WO2003008370A1 Substituted 4-aminocyclohexanols |
| 01/30/2003 | WO2003008362A1 Novel 3-aryl-2-hydroxy propanol derivatives and a process for their preparation |
| 01/30/2003 | WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 01/30/2003 | WO2003007990A1 Myosin agonist |
| 01/30/2003 | WO2003007976A1 High protein, bowman-birk inhibitor concentrate and process for its manufacture |
| 01/30/2003 | WO2003007951A1 A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 01/30/2003 | WO2003007950A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
| 01/30/2003 | WO2003007949A1 Bridged piperidine derivatives as melanocortin receptor agonists |
| 01/30/2003 | WO2003007933A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
| 01/30/2003 | WO2003007932A1 Body fat level controllers |
| 01/30/2003 | WO2003007923A2 Use of trifluoroacetyl alkyl-substituted phenyl derivatives, phenol derivatives, and benzoyl derivatives in the treatment and/or prophylaxis of obesity and accompanying diseases and/or secondary diseases |
| 01/30/2003 | WO2003007889A2 Therapeutic agents comprising pro-apoptotic proteins |
| 01/30/2003 | WO2003007888A2 Fat accumulation-modulating compounds |
| 01/30/2003 | WO2003007733A1 Protein-containing foodstuff comprising a cross-linking enzyme and a hydrocolloid |
| 01/30/2003 | WO2003007732A2 Pet food composition for regulating body weight and preventing obesity and related disorders in pets |
| 01/30/2003 | WO2003007689A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c |
| 01/30/2003 | WO2002092756A3 Insulin producing cells derived from human embryonic stem cells |
| 01/30/2003 | WO2002088079A3 Dual inhibitors of pde 7 and pde 4 |
| 01/30/2003 | WO2002079478A3 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders |
| 01/30/2003 | WO2002072078A9 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications |
| 01/30/2003 | WO2002068585A9 Tip39 polypeptides |
| 01/30/2003 | WO2002064160A8 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 01/30/2003 | WO2002059129A3 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
| 01/30/2003 | WO2002051355A3 Acetyl-coenzyme a carboxylase 2 as a target in fat regulation and insulin action |
| 01/30/2003 | WO2002050257A3 Method for the production of polyfructans |
| 01/30/2003 | WO2002010393A3 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| 01/30/2003 | WO2002010151A2 Method for producing lipoic acid and dihydrolipoic acid |
| 01/30/2003 | WO2002007773A3 Multi-component biological transport systems |
| 01/30/2003 | WO2002007765A3 REGULATORS OF PPARδ(β) AND THEIR USE IN THE TREATMENT OF OBESITY AND INSULIN RESISTANCE |
| 01/30/2003 | WO2002005795B1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2001090359A3 G-protein coupled receptors |
| 01/30/2003 | US20030023993 Nucleotide sequences coding polypeptide for use in the treatment of necrosis, septic shock and inflammation |
| 01/30/2003 | US20030023100 For therapy of inflammatory and allergic reactions, drug or alcohol abuse, diarrhoea, gastritis, ulcers, cardiovascular diseases, urinary incontinence, depressions, states of shock, migranes, narcolepsy, overweight, asthma, glaucoma, etc. |
| 01/30/2003 | US20030023085 For therapy and prophylaxis of condition or disorder mediated by a G-protein coupled receptor such as eating disorders, obesity, anxiety disorders and mood disorders |
| 01/30/2003 | US20030023079 For therapy of thrombosis in a mammal |
| 01/30/2003 | US20030023048 Chemical modification of proteins to improve biocompatibility and bioactivity |
| 01/30/2003 | US20030022944 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/30/2003 | US20030022942 Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion |
| 01/30/2003 | US20030022935 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents |
| 01/30/2003 | US20030022929 Method of using soluble epoxide hydrolase inhibitors |
| 01/30/2003 | US20030022914 Nitric oxide synthase inhibitors |
| 01/30/2003 | US20030022907 Anxiolytic agents and analgesics |
| 01/30/2003 | US20030022896 Protein-tyrosine phosphatase (PTPase); treating diabetes or Syndrome X; (R)-2-(2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho(2,3-b)thiophen-4-yl) -phenoxy)-3-phenyl-propionic acid |
| 01/30/2003 | US20030022891 Melanin-concentrating hormone (MCH); treating metabolic and eating disorders, such as hyperphagia, and diabetes; urea, thiourea and cyano-guanidine compounds of given formula |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022874 New 17-halogenated 19-nor steroids, preparation process and intermediates, use as medicaments and the pharmaceutical compositions containing them |
| 01/30/2003 | US20030022872 Possesses excellent binding property to vitamin D receptors; for treating diseases accompanied by abnormal calcium metabolism |
| 01/30/2003 | US20030022865 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 01/30/2003 | US20030022848 Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression |
| 01/30/2003 | US20030022845 Compositions comprising a mixture of bioflavonols |
| 01/30/2003 | US20030022840 Drugs for ameliorating impaired glucose tolerance |
| 01/30/2003 | US20030022836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 01/30/2003 | US20030022823 Glucagon-like peptide (GLP-1), an analog, or a derivative, is administered at a dose effective to normalize blood glucose after myocardial infarction in diabetic patients |
| 01/30/2003 | US20030022817 A protein hydrolysate to the preparation of a energy supplementation or metabolic nutrient, characterized in, that it is an animal or vegetable protein hydrolysate having a degree of hydrolysis of 1-50 |
| 01/30/2003 | US20030022813 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022812 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022283 Neuropeptide Y receptor Y5 and nucleic acid sequences |
| 01/30/2003 | US20030022277 Nucleotide sequences coding polypeptide or use in the treatment of eating disorders |
| 01/30/2003 | US20030022272 Method of inducing an antigen-specific anticytotoxic cell |
| 01/30/2003 | US20030022241 Detection of modulators of enzyme activity; obtain sample containing kinase activity, incubate with modulator, monitor diabetic response |
| 01/30/2003 | US20030022238 Methods of identifying agents which inhibit GPR-9-6 |
| 01/30/2003 | US20030022211 Nucleotide sequences coding polypeptide for use in diagnosis and prevention of psychological and nervous system disorders |
| 01/30/2003 | US20030021856 New use of ammonium compounds and/or urea |
| 01/30/2003 | US20030021843 Antidiabetic preparation for oral administration |
| 01/30/2003 | CA2682251A1 A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 01/30/2003 | CA2454418A1 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | CA2454189A1 High protein, bowman-birk inhibitor concentrate and process for its manufacture |
| 01/30/2003 | CA2454187A1 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
| 01/30/2003 | CA2454059A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 01/30/2003 | CA2454002A1 Regulator for amount of body fat |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453636A1 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452556A1 Protein-containing foodstuff comprising a coss-linking enzyme and a hydrocolloid |
| 01/30/2003 | CA2452541A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
| 01/30/2003 | CA2452354A1 Pet food composition for regulating body weight and preventing obesity and related disorders in pets |
| 01/30/2003 | CA2451881A1 Novel bisphosphonate derivatives, their preparation methods and uses |
| 01/30/2003 | CA2451530A1 Chemical compounds |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/30/2003 | CA2417842A1 Method for producing lipoic acid and dihydrolipoic acid |
| 01/29/2003 | EP1279744A2 Identification and use of molecules implicated in pain |
| 01/29/2003 | EP1279674A2 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| 01/29/2003 | EP1279404A1 Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| 01/29/2003 | EP1279403A1 Pernasally absorbable insulin preparations |
| 01/29/2003 | EP1279400A1 Modifying the fatty acid composition of cell membranes of organs and tissues |
| 01/29/2003 | EP1279332A2 Transgenic non-human mammal |
| 01/29/2003 | EP1278869A2 Proteases |
| 01/29/2003 | EP1278859A2 Human protein kinases and protein kinase-like enzymes |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278843A2 Rna metabolism proteins |
| 01/29/2003 | EP1278838A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278827A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |